To determine whether CRM1 in combination with BATF2 can serve as a more accurate prognostic marker, 184 human CRC samples were assigned into four groups based on the expression levels of CRM1 and BATF2 (Figure 4F). This evidence concerns the gene XPO1 and colorectal carcinoma.